Saxagliptin/metformin immediate release - AstraZeneca

Drug Profile

Saxagliptin/metformin immediate release - AstraZeneca

Alternative Names: Kombiglyze; Komboglyze; Metformin immediate release/saxagliptin; Metformin IR/saxagliptin; Onglyza/metformin IR FDC; Saxagliptin/metformin IR

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Biguanides; Dipeptides; Insulin sensitisers; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 11 Jul 2017 Saxagliptin/metformin immediate release is still in Preregistration for Type-2 diabetes mellitus in China (AstraZeneca pipeline, July 2017)
  • 01 Feb 2014 AstraZeneca acquires saxagliptin/metformin immediate release from Bristol-Myers Squibb
  • 31 Dec 2013 Preregistration for Type-2 diabetes mellitus in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top